Trillium Therapeutics (TRIL) Approved by FDA to Commence TTI-621 Phase 1 in olid Tumors and Mycosis Fungoides

August 17, 2016 7:06 AM
Trillium Therapeutics Inc. (Nasdaq: TRIL) announced that the US Food and Drug Administration (FDA) has provided the company clearance to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles